Brief: Nanoform's Nanotrastuzumab Matches Performance Of Herceptin Hylecta
12/02/2026 06:48
Feb 12 (Reuters) - Nanoform Finland Oyj NANOFH.HE: SUBCUTANEOUSLY ADMINISTERED NANOTRASTUZUMAB MATCHES PERFORMANCE OF HERCEPTIN HYLECTA IN MINIPIG STUDY BELIEVES DATA INDICATES THAT REFERENCE-LIKE SC EXPOSURE MAY BE ACHIEVABLE WITHOUT HYALURONIDASE Source text: ID:nMFN6jdTd1 Further company coverage: NANOFH.HE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Nanoform Finland Oyj
See all newsFinland's Nanoform Q2 EBITDA loss narrows on layoffs, cost cuts
Brief: Nanoform Q2 EBITDA EUR -3 Million
Brief: Nanoform Receives Positive Feedback From UK Mhra Scientific Advice Meeting
Finland's Nanoform Q1 revenue rises 45%, EBITDA loss narrows
Brief: Nanoform Finland Targets Cash Burn Below EUR 10 Mln For 2026